Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Thank you and hello everyone. Welcome to our fourth quarter earnings call and full year results. As customary, please note our forward-looking statements, which I will assume that you have read. So moving over to the agenda, we will begin today's call with an introduction and business highlights, followed by financial, commercial and R&D pipeline reviews before finishing off with key takeaways and Q&A with me. In the call today is Anders Vadsholt, chief financial officer, and Richard Jameson, chief commercial officer. So a quick overview of Camurus. We are a rapidly growing commercial stage biopharmaceutical company focused on developing and delivering innovative, long acting treatments for people living with serious and chronic illnesses. We have become a global leader in opioid dependence therapy with our products Buvidal and Brixadi. Our commercial reach covers Europe and Australia, and we are now expanding into the US as we gear up for upcoming product launches. At the core of our offerings is the FluidCrystal® technology, which supports advanced long-acting injectable treatments and has proven successful through both our commercial and clinical results and collaborations, alongside our meaningful investments in the R&D pipeline. We have maintained sustainable profitability since 2022, placing it in a good position for ongoing growth. Now turning to full year highlights. In 2025, we achieved several significant milestones that further strengthened our leadership in opioid dependence treatment and our ongoing expansion. We continued to build momentum with Buvidal and Brixadi, expanding their reach and impact across key regions. Importantly, the first of our new wave products received regulatory approval for acromegaly in both the EU and the UK, supporting our strategic expansion into the US. The commercial infrastructure is now firmly established, positioning the company for upcoming launches and long-term success in this critical market. During the year, we also entered a strategic license agreement with Lilly, opening new opportunities in the long-acting incretin therapy space. The year also marked substantial improvements in sustainability performance, evidenced by high external ratings and reinforcing our commitment to responsible and sustainable business practices. As a testament to our team's performance, full year revenues for 2025 continued their positive trajectory, reaching 2.3 billion SEK, while profit before tax simultaneously increased to just above 0.9 billion SEK, achieved while maintaining significant investments in R&D and expanding in the US. Fourth quarter results demonstrated a balanced performance with an overall positive conclusion for the year. Royalties in the US showed strong Year-on-Year growth of 47%, and increased 82% at Constant Exchange Rate (CER). Overall sales declined temporarily due to FX headwinds and a change in our UK distribution model. The launch of Oczyesa® in Germany represented a notable milestone, as it is the first European country to introduce this product to patients with acromegaly. Turning to R&D. We resubmitted the NDA for Oclaiz, which the FDA now has accepted with a due date in June. Additionally, we reported compelling Phase 1 results for CAM2029, and our strategic collaboration with Lilly progressed as planned. Financially. We delivered solid profitability, strengthened our cash position, giving us increased financial flexibility. And lastly, we entered a new licensing and commercialization partnership with Gubra in Denmark, adding another promising asset to our endocrinology pipeline. So with this, I will hand over to Anders to take you through the financial performance of the quarter and of the full year.
Thank you Fredrik. Overall, I'm pleased with the financial performance during the year. The figures I referred to in my presentation, in Swedish krona, Camurus reported quarterly revenue of 464 million, down from 553 million, a 16% decline compared to the same period last year, while quarterly product sales reached 342 million, reflecting a 27% decrease. This reduction is primarily due to a change in the UK distribution model. Consequently, we repurchased 93 million worth of inventory from our UK wholesaler. Quarterly royalty income from sales in the US increased by 47% year on year, reaching 122 million. A potential milestone payment from Braeburn relating to sales is now expected in 2026. Full year revenue reached 2.27 billion, up from 1.87 billion, representing a 21% growth, or 30% at constant exchange rate. Product sales increased by 6%, while royalty income increased by 87%. When reviewing operating costs, marketing and distribution expenses decreased by 12% during the quarter, but increased 77% over the year. The annual increase was mainly driven by the commercial rollout of Buvidal in Europe and Australia, as well as the company's expansion in the US. In R&D, we observed a 25% reduction in cost during the quarter and a 24% reduction for the full year. This reduction results from the completion of clinical trials in CAM2029 and CAM2056, with new trials scheduled for 2026. Some costs related to the SORENTO study have been deferred to 2026. The increase in general administrative expenses was primarily due to a change in the internal cost allocation model. Additionally, we have boosted our investment in digitalization throughout the organization. The operating result for the quarter decreased 32% to 113 million, while the full year results increased by 86% to 874 million, with product sales and royalty income mainly driving the increase. Looking at the quarter's cash flow, the cash position increased by 209 million, mainly driven by operating activities which contributed 111 million, and a change in working capital, adding 144 million. Investment reduced cash by 46 million, resulting in a net cash position of 3.7 billion, a 30% increase from the previous year. Moving to 2026 financial guidance. The key considerations for the guidance are anticipated market dynamics and competitive developments, pricing conditions and the reimbursement landscape, clinical progress and regulatory outcome, and not least, the current macroeconomic uncertainties. We expect an increase in OpEx to be primarily caused by organizational expansion and increased R&D activities. An additional 200 million would be allocated to expanding US operations in preparation of the Oclaiz launched mid-2026, and R&D expenses are expected to increase by roughly 150 million. We provide guidance on revenue and profit. We have shifted from reporting profit before tax to operating results. Revenues consist of product sales, including royalties and milestones. Potential license income from new and existing development partners is not included. Our full year 2026 outlook is as follows. Revenue guidance is 2.6 to 2.9 billion, an increase of approximately 21%. Operating result in the range of 0.9 to 1.2 billion, an increase of approximately 20%. The numbers are reported or measured at constant exchange rate. With that, I would like to hand over to Richard.
Thank you, Anders. So I'll start with Camurus markets. As already stated, invoice sales were impacted due to a one-time accounting adjustment associated with a change to the UK distribution model at the end of the period. Importantly though, across markets, the underlying in-market growth remains solid, growing at 5% quarter-on-quarter, with notable performances from Australia, which continues to grow from a high base and is maintaining its leadership position in the long-acting buprenorphine segment. And in the Nordics, Buvidal continues to gain market share, which was increased by a competitor's withdrawal from the market. And the UK showed improved growth, mainly from the criminal justice system, as NHS England funding is reaching those treatment centers. On a full year basis, overall growth was 17% at constant exchange rate versus 2024, with a growth spread across geographies. Those markets with high penetration, such as Australia and the Nordics, grew at 15% from their high bases. A positive contribution was achieved from the larger European markets that have lower penetration due to access issues; these markets grew in the region of 21%, and at the end of 2025, there were an estimated 7,000 patients currently in treatment, with a net gain of 3,000 patients in the quarter. There remains a significant growth opportunity for Buvidal, notably in those larger European markets. As I already mentioned, in countries where funding and access hurdles have been addressed, penetration is high in Australia, Nordics, Scotland and Wales, Buvidal share ranges from 26% to 70%, with an average of 35% of all patients. And we expect continued growth in 2026. In the larger markets where access is currently limited, Buvidal has gained a single-digit share of patients in treatment, representing a significant opportunity when the funding and infrastructure issues are addressed. In England and France, the main challenge remains the prioritisation for funding in this area. In Spain and France, there are restrictions on Buvidal access, either regarding which patients are approved for treatment, or limitations on the treatment setting where Buvidal can be prescribed. We achieved a notable success in Q4, where we reached agreement in Spain with the Spanish Ministry of Health to remove restrictions on the patient populations for Buvidal, allowing access to the large methadone segment. And in Germany, physician remuneration remains the hurdle. Additionally, we continue to expand geographically in other markets where our focus is penetration to deliver double-digit growth in 2026. Now, to address the access challenges in these high potential markets, the teams are focused and delivering on critical policy affairs programs that call for and drive improved patient access. On the next slide are some examples of the outcomes already achieved from these programs and the growing support from across stakeholder groups for broader access to long-acting injectable buprenorphine, all of which we expect to drive growth in 2026. Take these in turn. In the UK, the Home Office Select Committee, the Justice Committee, the Independent Review on Drugs, and a recent report from the experience in Wales have all called for improved access to long-acting injectable buprenorphine. We are already seeing good access in prisons, though challenges remain in the community setting, and we have ongoing discussions with the Department of Health to address this. In France, reports from both the Senate and the Assembly have similarly made calls for improved access, and some progress has been made in funding for Buvidal at both a national and a regional level in Germany. Again, there's wide stakeholder support from physician societies, patient organisations and policy makers such as the Drug Policy Group in the Bavarian Parliament for change in the remuneration system to allow access to innovative treatments. The progress on this is slow. However, it is understood that there are ongoing discussions on this topic with the regional and federal associations of physicians and the health insurers in Spain, as mentioned already. Restrictions on patient access have now been removed. With this growing policy support for better access, we continue to work with payers to find ways to deliver on changes that will allow more patients to benefit from the advantages Buvidal brings. Now moving across to the US, Brixadi continued its strong performance in the year with Q4 royalties of 122 million SEK, up 10% from the previous quarter and 47% year on year. For the full year, Brixadi royalty grew 113% at constant exchange rate versus 2024. According to our estimates, Brixadi has captured at least 30% of the long-acting buprenorphine segment in the US. The long-acting buprenorphine segment is now above 1 billion in annual sales, and looking ahead to 2026, continued market penetration is expected. The key areas of focus remain. Conversion of patients from daily sublingual buprenorphine. Note, there are an estimated 2 million patients who access treatment with sublingual buprenorphine annually. Also improving access for patients outside of treatment or in the criminal justice setting. And we and our partner continue to communicate the evidence base and the clear value proposition of Brixadi. So overall, we remain optimistic about the prospects for Brixadi in the US and the potential for significant growth in the coming years. And in parallel to this, we are preparing for the launches of Oczyesa® in Europe, the first monthly subcutaneous octreotide medication that enables convenient self-administration for patients and enhanced octreotide plasma exposure. The European launch has now been initiated in the wave one countries that have an estimated 4,000 to 5,000 acromegaly patients currently treated with first-generation SRLs. The response to Oczyesa® from physicians and patients has so far been encouraging, with a positive view on the product profile and the clinical data, and market research shows a high willingness to switch to Oczyesa® from current SRLs. In our first launch market, Germany, we've seen a strong start with the uptake. In the first month of launch, an estimated 20 patients, representing about 1% market share, showed high engagement with the advantages of simple self-administration. In addition, initial feedback from other payers has been favorable and pricing has now improved in the UK and Norway, where we are now ready to launch. And with the resubmission of the NDA for Oczyesa®, we're also gearing up, as Fredrik said, for the US launch mid-2026. The team is launch ready with a clear understanding of the market and developed go-to-market strategy that includes market access, advocacy and distribution plans. During the review time of the NDA, we will take the opportunity to build the sales leadership followed by the sales teams onboarding and look forward to the execution of the launch plan if approval is granted. And on this, I will hand back to Fredrik.
Thank you so much, Richard. I will continue with the brief summary of the R&D advancements in the fourth quarter. So, starting out with the progress in the Octreotide depot program for acromegaly, gastroenteropancreatic neuroendocrine tumors and polycystic liver disease, the overall clinical program for CAM2029 is nearing completion across indications. We have successfully wrapped up the program, which delivered strong results from two pivotal phase three studies and an open label extension in gastroenteropancreatic neuroendocrine tumors. SORENTO study is making solid progress and remains on track for reaching the critical readout of primary efficacy results in the second half of the year. Additionally, the open-label extension of the POSITANO study continues to advance following the achievement of positive results for the primary endpoint during the core phase of the study. Now, moving over to development updates by indication, we achieved significant milestones in acromegaly. As we mentioned before, Oczyesa was approved both in the European Union and the UK in 2025, marking a major regulatory success in the year. Following this, we launched in Germany in the fourth quarter and broadened our commercial presence in Europe. Turning to the US, we resubmitted the New Drug Application for Oclaiz to the FDA on the 10th of December. After receiving green light from our contract manufacturer partner, the FDA accepted this after year-end. As a Class Two review, this sets a target PDUFA date of June 10, 2026, positioning Oclaiz for potential US approval and market entry shortly thereafter. Moving over to GEP-NET and the ongoing Phase 3 study. As you know, SORENTO is the largest clinical study to date for GEP-NET using a somatostatin analogue, directly comparing CAM2029 with current standard of care. The study is progressing according to plan, with a target of 194 progression-free events required to reach the primary endpoint readout in the second half of the present year. Importantly, compared with earlier trials with SRLs in this indication, Sorrento has enrolled patients with more advanced disease, including a majority of grade two and grade three neuroendocrine tumor patients. As we await the results, our teams remain focused on robust study conduct, rigorous data cleaning, and maintaining the highest study quality to enable a rapid and reliable top-line result announcement. The upcoming results will represent a major milestone for Camurus, marking the culmination of nearly five years of patient treatment and study efforts. Commercially, this represents a significant opportunity for the company, with global peak sales estimated around 2 billion USD currently. Finishing off with CAM2029 in polycystic liver disease, where we are in the process of completing the 30-month extension phase. As mentioned before, our regulatory and clinical teams have prepared an end of phase two meeting with the FDA scheduled for March, to discuss the design of the pivotal phase three study. In summary, we achieved significant progress with CAM2029 across the three indications, and we anticipate an eventful period ahead. Moving over to the R&D pipeline. A clear highlight of the fourth quarter was the positive top line results from our phase one study of the monthly formulation of semaglutide Cam 2056, in patients with overweight or obesity. This study featured a randomized comparison to the current weekly semaglutide formulation, as well as dose escalations. The results exceeded our expectations and showed that Cam 2056 achieved faster and greater reductions in body weight and blood glucose compared to Wegovy, with a similar safety and tolerability profile up to the highest dose. This slide summarizes the Phase 1b study design for Cam 2056 with the five dosing regimens across 80 patients, using both randomized and dose escalation parts. The study allowed us to compare directly against weekly semaglutide and to define the optimal initiation and titration strategy for monthly formulation. On the next slide here. As you can see, CAM2056 delivered substantially greater reductions of body weight and A1c compared to the weekly semaglutide over the treatment period. By day 85, that is, after three months of treatment, Group four achieved a 9.3% weight reduction with CAM2056 versus 5.2% with weekly semaglutide dosed, according to label, and A1c declined by 0.44% versus 0.12%, which is in the significant clinical domain. The data clearly demonstrates the potential of FluidCrystal® based formulation of semaglutide and going forward, our next steps will be to build on the promising Phase 1 results. We are actively preparing for a Phase 2b study, planned to begin in the second half of the year. In parallel, our R&D teams are preparing the final product presentation, which will feature a new Autoinjector pen device to enhance dosing convenience for patients. The positive outcomes from the study not only support continued development of Cam 2056, but also provide strong validation for the FluidCrystal® technology platform. As such, these results reinforce the potential of using FluidCrystal® technology for additional long-acting incretins as well as other peptide-based therapeutics, including in our ongoing collaborations with Lilly and the partnership. The new partnership with Gubra. So with this, it's time to wrap up with some final comments. And I think we can say that 2025 was a year where Camurus made significant progress with major R&D milestones, solid growth, and high profitability. This year, we have defined our aims. With that, I mean 2026, we aim to expand our market leadership in opioid dependence treatment, to launch Oclaiz for acromegaly in Europe and the US (pending, of course, FDA approval), and to anticipate positive data readouts. New clinical trials will also begin for promising candidates like CAM2056. For further growth and diversification of our business, we will invest in our partnerships, intensify business development to secure new collaborations and potential strategic acquisitions. Our solid financial, operational, and scientific base gives us a clear path to sustainable value creation, and we are well positioned to make 2026 a transformative year. And with that said, I will thank you all for listening, and let's move over to Q&A.
Thank you, Fredrik. The first question comes from the line of Romy O’Connor from Van Lanschot Kempen. This year, we have clear aims. Romeo.
Hi. Thank you so much for the presentation. Two questions, if I can. The first, in the annual report, it says that the core components phase of the SORENTO trial is now set to be completed in H2 26. Can you clarify what this core component is? And, is the top line data still then estimated for mid to late 2026? And the comments on the new autoinjector pen device. Can you provide any more color on this? Is this just for the CAM2056 assets? Our solid financial, operational, and scientific base gives us a clear path to sustainable value creation, and we are well positioned to make 2026 a transformative year.
This year, we aim to achieve our strategic objectives. Romy. Well, with the core phase, we mean the randomized part of the study. So to the point where we can start reading out the data. And as to the auto-injector for Cam 2056 that we are working to develop. We have been working with this for quite some time, and it will be a new device adopted specifically for CAM2056.
Claire, thank you so much.
Does that answer your questions?
Yes it does. Thank you.
Thank you.
The next question is from Gonzalo Arteaga from Danske Bank. Please go ahead. Gonzalo.
Hi, guys. Gonzalo from Danske Bank. Thank you for taking my questions. I have a couple of them. And the first one, I'm trying to understand the FX impact, especially in the US. Could you give us some color on the FX impact that you see there in the US? Peak to trough is 17% headwind, if I understand correctly, on USD to Swedish krona. So how did you end up with 35% headwind? And the second question is on your 2027 goals, have they changed based on how 2025 closed? I see that you guys still target 100,000 patients. But do you have any words on margin development? Are you still targeting around 50% for 2027, and any information on the top-line goal for that year would be appreciated. I'll leave the first question over to Anders.
So I think I'll leave the first question over to Anders. When it comes to the dollar rate and its impact on our FX rates.
So, we've had a lot of fluctuation in the currencies during the year, primarily in the Australian dollar and the US dollar, as you state. So, it all depends on when we book it; it is more a technical thing regarding the booking of invoices and so on. That's where you see the effect. But we have seen a decrease over the year from January all the way to December.
Gonzalo, can you repeat the second question?
Yes. It's on your 2027 goals or targets that you have disclosed in the past. What do you have to say in terms of your margin approach? Are you still targeting around 50% for your Ebit margin and on top line, any words on that also?
So we established the vision for 2027 in 2022. And we are working conservatively and with a high dedication to achieve that. Obviously there is still a way to go, but we are committed. We maintain our goals currently. Including the margin goals of approximately 50%.
What do you have to say in terms of your margin approach? What do you have to say in terms of your margin approach?
I want to highlight that this is and remains a vision for the company.
The next question comes from Pauline Hendrickson from Van Lanschot Kempen. What do you have to say in terms of your margin approach? Pauline.
Hi. Sorry, my question's already been answered. What do you have to say in terms of your margin approach?
Okay, thanks. The next question is from Christopher from SEB. What do you have to say in terms of your margin approach? Christopher.
Yes. Hi there. Thank you for taking my questions. So my first question is just whether. So to what extent your guidance range might reflect any concern about ongoing FX headwinds because, obviously, it was a headwind for your 2025 delivery and you cut the guidance partly as a result. And obviously it's only going to get worse. So you're fighting with one hand tied behind your back. That's my first question. Thanks.
And do you want to comment on.
So we have definitely taken the currency exchange risk into consideration when providing the guidance. So and then, we've made a thorough analysis on several expectations for the development. And also, I would say, when we look into the US this year, we've predominantly had income. Next year, we'll also begin to have some expenses due to the build-up. So, it's now a more natural hedge. But of course, we are very much exposed to the US dollar.
Okay, thanks. That was the first one. Secondly, I noted that you had mentioned the milestone from Braeburn in 2026. Is it fair to assume that that's in guidance? And can you give us an indication of the size? Is it similar to the last one you got from them?
So it's a good question. Obviously we did not realize the milestone in 2025. So that, but there are good reasons to expect the first milestone. We haven't received any sales milestones yet from the collaboration, but the prospects for it are positive. There are good reasons to expect it in 2026. The size, one could comment. I don't think we have given any exact size. It's the smaller of the three. And the total amount is $75 million.
And do you want to comment on...? And do you want to comment on that? That's helpful. Then my next question is on. So, SORENTO, is it likely to be in the early or late second half at this point, do you think?
I think there is still some uncertainty about that. It depends on the accrual rates month by month and quarter by quarter. And of course, it's very difficult because it's an event-driven trial. It's very difficult to give exact predictions. And it may vary between how patients were enrolled. We have, of course, our models. But they do give quite a wide interval. Still. So we will get some more updates here. Of course, in the early part of the year, and the more data we get, the better we are able to give an idea about when exactly we can start to close and read out data.
Okay, thanks very much. Those are my housekeeping questions. Then I have a question on revenue per patient because over the last nine months, you can see a dip for Buvidal® of about 25%. It looks like, how much of that is actual price pressure versus FX? I think there is still some uncertainty about that. And I have other questions.
If it's okay, I'll leave it over to Richard to explain.
Yeah. So, there's the first. First answer is the price is pretty stable across our markets. We're maintaining that with our programs. So there is obviously a country mix, depending on the volume there because there are different prices in different markets, and then the rest will be down to FX.
But they do give quite a wide interval. Okay, thanks very much. I think there is still some uncertainty about that. So then, I guess if you could, is there a little bit more you can give us in terms of what's going on in the UK and Germany, in terms of the status and France? I should say you did comment a little bit, but do you have any hints on whether momentum is gathering, let's say for Germany, for example, with remuneration reform. Thanks.
Yeah, sure. I think good questions. I'll start with Germany then. It is the one you mentioned there. As I said, there's quite a lot of support for change in this remuneration system. It's something that we cannot be involved with as an organization, but we understand there are ongoing and advancing discussions between both national and federal physicians associations and the health insurances to change that so they can open up access. And we've seen the growth. A report came out of the Bavarian drug strategy group of the Bavarian parliament calling for the same thing. So I think there's growing momentum there. It's a bit unsure when the outcome will come, but we know there are ongoing discussions. And for the UK, there's a question there. We know Wales and Scotland are going very well. They have high penetration; they have funding available. England is our challenge. But again, there's clear demand from across many groups, as I said, from criminal justice, from healthcare, from healthcare professionals and patients for funding. We've seen NHS England, which is responsible for treatment in prisons, making a significant commitment to funding that started in mid-2025 and is continuing, and hence the growth we are seeing in the UK is coming mostly from prisons. We know the UK government have now announced a three year funding settlement for public health, including a ring fenced proportion for opioid dependence treatment. So, we're in dialogue with the Department of Health, NHS, and other stakeholders to identify ways that funding can be allocated to long-acting buprenorphine to meet the demand that's there.
Okay. That's very helpful. Can you give us the gating events that remain for these developments in Germany, the UK, and France, such as specific events?
So, I think that's very difficult. This is policy change. With the remuneration, we're not involved in that. So it's very hard to be able to judge when the timing on those things is.
It is the one you mentioned there. And I appreciate that, okay. Is the one you mentioned there? Those are my questions.
Is that the one you mentioned?
The next question is from Viktor Sundberg. That is the one you mentioned. Victor.
Yes. Thanks for taking my questions. Yeah. Continuing. Maybe on the UK. I guess this is perhaps the main uncertainty going into 2026. Can you give a bit more insight into if there's any stocking left at distributors that could impact sales here in 2026? And just remind us if and when funding is expected to trickle down to clinics to improve sentiment in the UK. So there's no more stock in the channels.
Yeah. Sure, sure. So there's no more stock in the channels once that's done. The answer is, the NHS year runs from April to March. So the latest announcement from the government will be effective from April. How long that will take for the funding to reach the clinics is a moot point. We know that this year there was an announcement and it's been very slow in reaching the clinics, which is one of the reasons that it's been a bit slower than we anticipated after the announcement. So we obviously are doing everything we can to encourage responsible people to make that available to patients as soon as possible, because there is a clear unmet need. And patients are waiting to go on to treatment with Buvidal®.
Yes. So maybe it's more towards the end of 2026 or second half. Is that fair?
I don't think we can say that now. I think there is potential. It could come. We know there's been a delay in 2025 and people are putting pressure on that. So it could come earlier.
Yes. And just on guidance also, could you specify a bit more what you mean with pricing conditions and reimbursement as something that could impact guidance both on the upside and downside? And what the most important points are also in the US to keep in mind when you talk about competitive developments that you mentioned in your guidance.
Yeah. When it comes to pricing. Of course, it is our current understanding of the pricing landscape, most importantly for Buvidal and Brixadi. And we don't see that there are big differences from year to year, at least not from 2025. It's relatively stable, the landscape there. When it comes to Oczyesa, we don't have that many uncertainties either, because we got the approval, of course, in Germany of the price. And we have proceeded now with Norway and other markets. So I think that's what we mean. We are building it on our current understanding of the pricing situation and reimbursement willingness in our different markets.
Okay. And just had a final one also on FluidCrystal® maybe in general, you have had a lot of data pointing to that FluidCrystal® technology. FluidCrystal also enhances existing drugs bioavailability in your trials. And I guess we saw evidence of this again in your trial with semaglutide. But have you done any more analysis on that, on your semaglutide data supporting that bioavailability is higher with FluidCrystal®? FluidCrystal-enhanced semaglutide versus Wegovy? And do you expect this efficacy advantage to be sustained in your next trial? Do you get both long-acting but also increased efficacy here for this product? And also maybe related there? What would be the difference here? Difference here in the Phase 2b trial? Is it just more patients or any other key changes that we could expect? Thanks.
That's a really good question. When it comes to that, I don't think we have talked about bioavailability specifically; what we referred to was that we had the same Cmax concentration at a much higher dose with CAM2056. At a four times higher dose with CAM2056 as the now approved product is. So we have obviously done a lot of analysis on the relationship between our different variables in the study and time and so forth. Going to the Phase IIb study, the main question will be to see how the weight reduction is developing over a longer period of time. So it will be a significantly longer study. Although we have now identified what we believe is the optimal dosing regimen. Although we have now identified what we believe is the optimal dosing regimen. We will definitely produce new data that will be presented in various different settings on the PK/PD relationships. But for the specific question about the study, it will be a longer study. And it will be a controlled study in the first case. And then in parallel with that, we will do the preparations for Phase 3 development.
So, we will definitely produce new data that will be presented in various different settings on the PK/PD relationships. We will definitely produce new data that will be presented in various different settings on the PK/PD relationships. That's very clear. So, we will definitely produce new data that will be presented in various different settings on the PK/PD relationships.
Next question from Oscar Haffen Lamm from Stifel. And we will definitely produce new data that will be presented in various different settings on the PK/PD relationships. Oscar.
Yes. Hi. A couple of questions on my side. The first one maybe on the guidance for 2026. Could you give us a bit more granularity on your expected contributions from Buvidal, Brixadi and Oczyesa in this guidance?
Yes. We are. As we said in the report, we are expecting to continue to grow in the region of what we saw in 2025. So I think that's clear. We also have a view that we're expecting good performance from the US and Braeburn with the Brixadi development. So that's of course a very important component of the development or the expected development for 2026. I think we have to say that Oczyesa is, of course, going to be launched in a few markets, but it's going to be early in the launch cycle. Compared to the developments that we have, of course, for in the opioid dependence area. So the contribution there will be low. And I think you should focus on the big components. And then of course, we have excluded any potential revenues from ongoing development programs. And, they are, as always, binary. So we thought it was better to leave them out. But there is, of course, the potential for some upside in that range.
Okay. Thank you. Then another question. You mentioned your objective of 100,000 patients, and by the end of 2027, this would obviously mean a strong acceleration in the next two years. Maybe higher than what you've shown in the past. So my question is, where will this growth come from? Or are you already seeing some signs of acceleration in Europe, for example?
I'll leave that to Richard.
Yes. As I said, we saw growth of 20% plus in the big European market. So, Germany, the UK, France, and Spain. And that's the big opportunity here. We're working very closely with a whole group of stakeholders to try and improve access here. Some of those could be quite material if successful, that give access to many more patients. So that's why we believe the 100,000 is still possible in that time. But it is predicated on solving some of those funding challenges that we're facing, which we're making good progress in doing.
Okay. Thank you. And just one last question. What is currently the proportion of Buvidal® sales that are coming from the UK? I don't know if you've already disclosed this or not.
I don't think we have disclosed it. And we're typically not giving the relationship between different markets.
Okay. That's all for me. Thank you.
Next question is from Josh Allen from ABG. Please go ahead. Josh.
Hi. This is George. I have a couple of questions. First, I'm wondering if you can give any insight into where the roughly 20% year-over-year growth in German patients is coming from. And then secondly, regarding Oczyesa®, when do you expect to launch in France, Spain and Italy? Thank you.
So, the first question you had was regarding Buvidal?
Yes. Regarding what kind of German patients are you getting or adding at the moment?
Oh, okay. Yeah. I'll leave it to Richard.
The 20%?
Yeah, I leave it to Richard.
Yes. So it's a mix. There are patients in the criminal justice setting that are outside the remuneration challenge, which we see growing. There are other physicians who are more open to prescribing a long-acting injectable in the community setting, and that's coming from there. So it's a mix. I can't say there's one specific segment, but the prison setting is key, and so is the community setting.
And when it comes to the other question, we are starting in the wave one countries in parallel. We are doing our market access work for the rest of Europe. And we will announce that, as you have seen with Buvidal, we continue to add new countries to the markets, even in its seventh year of commercialization. But I wouldn't say that we are expecting to see France on board, for instance, until at the earliest next year.
Hello. So, your first question was regarding Buvidal?
Thank you so much.
Next question from Dan from Pareto Securities. So, your first question was regarding Buvidal? Dan.
Hello. Just two more questions from my end. And one would be if you could share any comments with regards to how frequently you communicate with Eli Lilly, for instance, on a monthly basis. And are they happy with the data? And the second question would be just on the inventory there that you got back for the UK, how long is the shelf life for that, or can you reallocate that to other geographies if the UK would take more time? Yeah.
So on the first question, I have to say that, through our contractual relationship with Lilly, we are not able to communicate too much about the progress on important matters that are material to the company. We will progress and communicate. So, I think the information that is available now is what we can say about the current state of that collaboration. So on the second question, Anders.
We can definitely sell the product continuously. It is. So there's no question about that. So that's a very simple question. Reply to that one.
We have 36 months' shelf life on the product. So, typically that's not the problem for us.
Just two more questions from my end. And the second question is regarding the inventory you got back for the UK: what is its shelf life, or can you reallocate it to other geographies if the UK process takes more time? On the first question, through our contractual relationship with Lilly, we are not able to communicate too much about the progress on important things that are material to the company.
The next question from Matthias Bloom from Handelsbanken. On the first question, I have to say that through our contractual relationship with Eli Lilly, we are not able to communicate too much about the progress regarding important things that are material to the company. Matthias.
Thanks so much for taking my questions. I have two, so I'm coming back to this 100,000 patient target. With the net additions of 30,000 required to get there, should we think of net patient wins as linear from here? Or should we think of them rather as back-end loaded as more and more reimbursement hurdles are removed. And then secondly, for the revenue target of 4.5 billion kroner for 2027, shared at the CMD in 2022. At the time, the composition was 3 billion kroner from Buvidal and 1.5 billion kroner from pipeline. When I look at the informed consensus, it's largely at the 4.5 billion kroner level, but the composition is different: 2.6 billion kroner from commercial products and 1.9 billion kroner from pipeline. So I'm curious to hear if you have any feedback or thoughts on that composition, not least in light of some of the pipeline contribution being delayed due to CDMO inspections, as well as slower accrual events in the SORENTO trial. Thanks so much.
At the time, the composition was 3 billion kroner from commercial and 1.5 billion kroner from pipeline.
I'll take the first one on the pickup of patients. I don't think there's a clear answer on this one because it depends on when we achieve the funding. So yes, obviously it's more likely to come later as we get there, but we're in quite advanced discussions with some areas that we could move more quickly. So that would depend on some changes that we need to make in discussions with the stakeholders involved in this. So I don't think there'd be a clear answer on that.
We also see a contribution from the expansion into new markets. Some of them have responded relatively slowly like Portugal. But we do see significant growth opportunities. So there is a mix there, and it's not easy to give you a precise breakdown. So far, we have been quite linear as was shown in the figure here earlier. So we need to pick up some more patients to reach 100,000 by the end of 2027 for sure. And. The 4.5 billion. At the time, the composition was 3 billion kroner from commercial revenue and 1.5 billion kroner from pipeline. The mix, obviously, in five years things happen in terms of the different programs advancing, but we are maintaining our ambition. You see how Buvidal® is evolving, and its contribution can be close to where we were expecting it. We have uncertainty about how quickly the... Brixadi sales will continue growing. We are hopeful there, of course, that these will be two major contributions: the delay in SORENTO, not in trial execution but in the event rate, may have an impact. And in that case, we will need to reach the goal; we will need to add additional revenues on top of this. Of course, we also have a number of milestones that can come in in 2027. But I would say overall we are not that far from the distribution that we mentioned in the 2022 Capital Markets Day, but obviously we weren't exact and will not be exact.
Thanks so much.
Next question is from Erik Hultgård from DNB Carnegie. Please go ahead. Eric.
Yes. Hi. Thanks for taking my questions. The first is what drove your decision to change the distribution model in the UK, and what impact did the timing of the decision, i.e. why now? And my second question relates to Oczyesa®, and the 20 patients that you have on therapy in Germany, is this mainly switch patients or are you also getting naive patients? And where do the switches come from, is it those on Sandostatin and Somatuline, or just Sandostatin? And where do the switches come from? Are they from patients on Sandostatin and Somatuline, or mainly from Sandostatin?
Okay, I'll leave the first question to Anders.
Yeah. So it came from volatility in the UK market. So, that caused us to more or less align the UK model with the rest of our distribution strategy. That's why we went to a different model. And also, because we have the upcoming launch, and when considering future accounting principles and reporting requirements, especially for IFRS 15 and IFRS 16, this model is much more suited for us. So that was why we did it, and it made sense to do it by the end of the year. So. So it was very clear.
And on the patients, I would say that all of them were switches from both treatments. We should, of course, be aware that there was only basically a little one and a half months or so recruitment time since the launch and availability of product in the market. And I think we saw a good pickup in that time period. And I think we'll see continued progress. The positive note is that most patients in Germany are on treatment. So, there are many fewer coming in, new patients per month or per time period. So this is a very good signal for us. And it seems to be progressing nicely also into the early part of this year. So we are happy with that. But I think you should assume that most of our patients will come from switches of current treatment.
All right. That caused us to more or less align the UK model with the rest of our distribution strategy. Then, just to follow up on Brixadi, do you expect a similar pattern in Q1 of this year as last year, when the buprenorphine market declined by double digits in Q1 versus Q4?
I think there is a change now because we obviously had the situation with the change from the Covid times that we saw impacting the first part of 2025, as there were still patients who didn't need to obtain new prescriptions due to allowances, and I don't think that dynamic remains. So we expect to see less of a dip in Q1, if any. It's too early. I don't have that information, but I think that's the situation.
Thank you so much. Thank you so much.
Gonzalo has a follow up from Danske Bank. So, SEB also has a follow-up. Gonzalo.
Yes. Hi. Hi. Then, just to follow up on Brixadi, do you expect a similar pattern in Q1 of this year as last year, when the buprenorphine market declined by double digits in Q1 versus Q4? It's one on PLD. And could we assume that you will start a Phase 3 this year if you have the end of Phase 2 meeting now in March? If I heard correctly. And if so, is this baked into guidance? Then, just to follow up on Brixadi, do you expect a similar pattern in Q1 of this year as last year, when the buprenorphine market declined by double digits in Q1 versus Q4?
So the important thing here is that we are, of course, seeking the agency's advice on the study design of the PLD study. And should we get perfect alignment with them in the first meeting, then there's definitely a probability. But even so, I wouldn't say that it would impact our R&D costs significantly. And they are baked into the current expectations or financial results expectations.
Gonzalo has a follow up from Danske Bank.
I think there is a change now because obviously we had the situation with changes from the Covid times that we saw impacting the first part of 2025, as there were still patients who didn't require new prescriptions due to the allowances introduced during that period, and I don't think that dynamic remains. So, SEB also has a follow-up. Then, just to follow up on Brixadi, do you expect a similar pattern in Q1 of this year as last year, when the buprenorphine market declined by double digits in Q1 versus Q4? Christopher.
Yes. Thank you for taking my follow up. Two, if I may. First, just for one clarification on the UK funding, is there any kind of clawback or rollover on the funding that was allocated for 25? And if there were a rollover, how would that impact the 2026 funding allocation? Thank you for the first one.
I think there's unlikely to be a rollover. But there is new funding for 2026 announced a couple of months ago now. So, some of the public health grant is distributed among various public health requirements, and some of it has been ring-fenced specifically for the treatment of drug and alcohol.
Thank you for taking my follow-up. So, of which, some of the public health grant is distributed among various public health requirements, and some has been ring-fenced specifically for treatment of drug and alcohol dependence. That's helpful. And then the second question is on the runway remaining in the EMEA region. And I guess within that also particularly Australia, how much more penetrated can long-acting injectables get in those markets? Two, if I may.
Yeah, I think there's still a regional opportunity. There are still reasonable numbers of patients on sublingual, many of whom will benefit from moving to a long acting. And there's also the methadone segment. And we're seeing increasing demand from patients to move to a long-acting treatment from methadone. It's a harder transfer. But the experience that people are gaining and how to do that is growing all the time. And we're seeing firstly demand growing and also the numbers of patients moving away. In Australia, for example, we're seeing methadone gradually declining. But there's still, we have around 35% share for long-acting. So that means there's 65% of people still available. Some of those will want long-acting.
I think we have said earlier that we believe that we could, ideally or even potentially exceed that, but long-acting injectables could reach up to 50% share. And so there is significant growth opportunity left in our view. But we'll see how it continued developing very well in 2025. And we haven't seen any signs yet that it will stop.
Great. Thanks so much.
The next question is from Sean Hammer from Jefferies. Please go ahead. Sean.
Hey, thank you for taking my questions. I've got three, if that's okay. Could I actually just press you on what the guide actually bakes in for Brixadi growth in 2026. I know it was asked before, but could you perhaps compare that to how Brixadi performed last year and what that would look like, the momentum in 2026?
I think what we said is we are believing that Buvidal will continue to grow in a steady fashion, and the remainder of what is baked in should be essentially Brixadi growth according to our projections.
The broader community-based funding. Hey, thank you for taking my questions. Great. And then my next question, please. Is, with the end of phase two conversation that you have with FDA in March for the PLD indication, where does that place potential phase three start and therefore the timing of the costs for that study?
Well, yeah. Importantly, it depends, of course, on which response we get from the agency. And starting a Phase III study and having the first patient treated typically takes at least nine months and probably a little longer than that.
Unless it makes sense. And then just my final question, please. Could you just clarify the England funding situation? So there's funding that was meant to arrive from last year, but never hit the clinics. When is that expected? And then you said, is there another round of funding that could come or be communicated by April that would then hit in 2H. Could you just clarify the timing of the funding?
Yeah. So, there are three sources. Firstly, the NHS England funding for prisons, which is reasonably significant, is already in place in clinics and it's driving growth in the UK. The broader community-based funding. That's the bit that struggled to come through. We don't know really what's going to happen in Q1, but what we do know is from Q2 onwards, from April, when the NHS year starts, there is this new committed funding by the government for public health, of which a large proportion is allocated specifically to drug and alcohol addiction. So we anticipate that coming in; we anticipated it last year as well. And it didn't reach it. So we'll have to wait and see. But I think the call for access to long-acting buprenorphine is very clear from various sectors. And we are confident that it's going to come through in 26 at some time.
Thanks so much. So that's the main target for us.
The last one is from Romy. Follow up from Van Lanschot. Kempen. We don't know really what's going to happen in Q1, but what we do know is from Q2 onwards, from April, when the NHS year starts, there is this new committed funding by the government for public health, of which a large proportion is allocated specifically to drug and alcohol addiction.
Hi. So that would be in endocrinology, rare oncology and potentially other rare disease indications and CNS. Just one follow up from me. Can you please provide some more color on your M&A and BD priorities for 2026? And are there any specific criteria or areas that you are looking at? So that's the main target for us.
Yeah. Nothing has really changed from the previous year. We are looking, as I said, our main target is pre-commercial or commercial assets that are synergistic to our current business in Europe, the US, or a more global setting. So that's the main target for us. So that would be in endocrinology, rare oncology and potentially other rare disease indications and CNS. And then we are working more exploratively, of course, also with early potential developments including licensing transactions and early licensing. Just to fill the early pipeline. But I would say our core focus is on late-stage opportunities, as mentioned earlier.
We don't really know what's going to happen in Q1, but what we do know is from Q2 onwards, from April, when the NHS year starts, there is this new committed funding by the government for public health, a large proportion of which is allocated specifically to drug and alcohol addiction. Thanks so much.
No more questions. So I have the word back to you, Frederik.
So thank you, everybody. I think and hope you see that we have a solid foundation for the year to come. And I look forward to updating you all together with the team on our Q1 presentation and meeting you in between. So thank you very much for listening in and asking very insightful questions. Thank you.



















